晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响

  目的  研究晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响。   方法  收集经病理学确诊且有可评价病灶的晚期肺腺癌患者40例，所有病例均有表皮生长因子受体（epidermal growth factor receptor，EGFR）突变状态检测结果，均采用含培美曲塞方案化疗，以总有效率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）为研究终点进行回顾性分析，比较两组间的疗效差异。   结果  EGFR野生组和突变组总有效率分别为44.4%（8/18）和31.8%（7/22）（P=0.412），疾病控制率分别为88.9%（16/18）和81.8%（18/22，P=0.673）。EGFR野生组中位PFS较突变组延长（8.9 vs. 5.3个月，P=0.046）。   结论  晚期肺腺癌EGFR突变状态对培美曲塞的疗效有影响。 

Role of EGFR mutation status in patients with advanced lung adenocarcinoma treated with pemetrexed

  Objective  To assess the role of EGFR mutations on pemetrexed response in patients with advanced lung adenocarcinoma.   Method  Forty pulmonary adenocarcinoma patients with evaluable lesions were retrospectively screened.They had been treated with pemetrexed-included chemotherapy and had EGFR gene test results. The evaluation endpoints were overall response rate, disease control rate and progression free survival.   Result  No significant statistical difference was seen in overall response rate(ORR)(44.4% VS 31.8%, respectively) and disease control rate(DCR) (88.9% VS 81.8%, respectively) between EGFR wild group and EGFR mutation group, but patients in EGFR wild group had longer progression free survival(PFS) (8.9 months VS 5.3 months; P=0.046).   Conclusion  EGFR mutation status can influence the efficacy of pemetrexed.